Takeda Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Takeda Pharmaceutical Co
TAK Stock  USD 15.18  0.17  1.13%   
Takeda Pharmaceutical financial statements provide useful quarterly and yearly information to potential Takeda Pharmaceutical Co investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Takeda Pharmaceutical financial statements helps investors assess Takeda Pharmaceutical's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Takeda Pharmaceutical's valuation are summarized below:
Gross Profit
3 T
Profit Margin
0.0454
Market Capitalization
47.4 B
Enterprise Value Revenue
2.4711
Revenue
4.6 T
There are currently one hundred twenty fundamental trend indicators for Takeda Pharmaceutical Co that can be evaluated and compared over time across competition. We recommend to double-check Takeda Pharmaceutical's current fundamental drivers against the all of the trends between 2010 and 2025.

Takeda Pharmaceutical Total Revenue

5.15 Trillion

Check Takeda Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Takeda Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 879.1 B, Interest Expense of 185.5 B or Selling General Administrative of 783 B, as well as many indicators such as Price To Sales Ratio of 1.67, Dividend Yield of 0.0417 or PTB Ratio of 0.98. Takeda financial statements analysis is a perfect complement when working with Takeda Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.

Takeda Pharmaceutical Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets18.2 T17.4 T9.2 T
Slightly volatile
Common Stock Shares Outstanding1.3 B1.4 B1.6 B
Slightly volatile
Short and Long Term Debt Total5.8 T5.6 T2.9 T
Slightly volatile
Other Current Liabilities1.8 T1.7 T813.1 B
Slightly volatile
Total Current Liabilities2.8 T2.7 T1.6 T
Slightly volatile
Total Stockholder Equity8.8 T8.4 T4.2 T
Slightly volatile
Property Plant And Equipment Net2.4 T2.3 T1.1 T
Slightly volatile
Current Deferred Revenue120.1 B126.4 B321.9 B
Pretty Stable
Retained Earnings1.4 T1.3 T1.6 T
Slightly volatile
Accounts Payable187 B367.9 B223.6 B
Slightly volatile
Cash587.6 B412 B556.8 B
Pretty Stable
Non Current Assets Total15.2 T14.4 T7.2 T
Slightly volatile
Cash And Short Term Investments722.1 B412 B625.3 B
Very volatile
Net Receivables549.4 B802.3 B590.8 B
Slightly volatile
Common Stock Total Equity2 T1.9 T926.1 B
Slightly volatile
Short Term Investments12.9 B13.6 B62.7 B
Slightly volatile
Liabilities And Stockholders Equity18.2 T17.4 T9.2 T
Slightly volatile
Non Current Liabilities Total6.7 T6.3 T3.4 T
Slightly volatile
Inventory1.5 T1.4 T633.6 B
Slightly volatile
Other Current Assets233.4 B222.3 B119 B
Slightly volatile
Total Liabilities9.5 T9 T5 T
Slightly volatile
Property Plant And Equipment Gross3.9 T3.7 T1.5 T
Slightly volatile
Total Current Assets2 T2.9 T2 T
Slightly volatile
Short Term Debt443.5 B422.3 B301.2 B
Slightly volatile
Common Stock2 T1.9 T926.4 B
Slightly volatile
Good Will6.5 T6.2 T2.8 T
Slightly volatile
Intangible Assets5.2 T4.9 T2.7 T
Slightly volatile
Other Liabilities713.1 B625.7 B483.2 B
Slightly volatile
Property Plant Equipment1.1 T1.9 T864.3 B
Slightly volatile
Cash And Equivalents382 B613.6 B351.9 B
Slightly volatile
Net Invested Capital10.4 T13.9 T7 T
Slightly volatile
Capital Stock1.8 T1.9 T1.7 T
Slightly volatile

Takeda Pharmaceutical Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization879.1 B837.2 B410.9 B
Slightly volatile
Interest Expense185.5 B176.7 B91.9 B
Slightly volatile
Selling General Administrative783 B1.2 T767.5 B
Slightly volatile
Total Revenue5.1 T4.9 T2.7 T
Slightly volatile
Gross Profit3.4 T3.3 T1.8 T
Slightly volatile
Other Operating Expenses4.9 T4.7 T2.5 T
Slightly volatile
EBITDA587.5 B1 T602.1 B
Slightly volatile
Cost Of Revenue1.7 T1.6 T863.5 B
Slightly volatile
Total Operating Expenses3.2 T3 T1.6 T
Slightly volatile
Selling And Marketing Expenses126.6 B130.2 B122.1 B
Slightly volatile
Research Development480.1 B839.4 B450.3 B
Slightly volatile
Interest Income12.3 B13 B23.3 B
Pretty Stable
Reconciled Depreciation561.5 B837.2 B390.4 B
Slightly volatile

Takeda Pharmaceutical Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow617.5 B480.2 B577.1 B
Pretty Stable
Depreciation879.1 B837.2 B410.7 B
Slightly volatile
Dividends Paid346.8 B330.3 B203.6 B
Slightly volatile
Capital Expenditures580.5 B552.8 B233 B
Slightly volatile
Total Cash From Operating Activities433.7 B823.8 B492.6 B
Slightly volatile
End Period Cash Flow626.2 B412 B550.9 B
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.671.753.7317
Slightly volatile
Dividend Yield0.04170.03970.0295
Slightly volatile
PTB Ratio0.981.032.6745
Slightly volatile
Days Sales Outstanding95.7868.6887.9823
Slightly volatile
Book Value Per Share4.4 K4.2 K2.6 K
Slightly volatile
Operating Cash Flow Per Share433412318
Slightly volatile
Stock Based Compensation To Revenue0.00910.0150.0115
Slightly volatile
Capex To Depreciation0.880.760.5768
Pretty Stable
PB Ratio0.981.032.6745
Slightly volatile
EV To Sales5.452.944.4249
Slightly volatile
Inventory Turnover2.441.361.8612
Slightly volatile
Days Of Inventory On Hand154278230
Slightly volatile
Payables Turnover5.045.154.7699
Very volatile
Sales General And Administrative To Revenue0.460.320.3288
Slightly volatile
Research And Ddevelopement To Revenue0.20.17120.1838
Slightly volatile
Capex To Revenue0.110.10.073
Slightly volatile
Cash Per Share634348416
Pretty Stable
POCF Ratio9.9210.4541.4069
Slightly volatile
Capex To Operating Cash Flow0.330.60.5827
Very volatile
Days Payables Outstanding10793.8287.3558
Very volatile
EV To Operating Cash Flow13.013.6943.605
Pretty Stable
Intangibles To Total Assets0.610.580.5069
Slightly volatile
Current Ratio1.211.271.5297
Slightly volatile
Receivables Turnover3.475.54.3035
Slightly volatile
Graham Number1.8 K2.8 K2.2 K
Slightly volatile
Shareholders Equity Per Share4.4 K4.2 K2.5 K
Slightly volatile
Debt To Equity0.630.60.5732
Slightly volatile
Capex Per Share290277139
Slightly volatile
Revenue Per Share2.6 K2.5 K1.6 K
Slightly volatile
Interest Debt Per Share3 K2.9 K1.8 K
Slightly volatile
Debt To Assets0.30.290.2559
Slightly volatile
Enterprise Value Over EBITDA18.1211.2127.3585
Slightly volatile
Short Term Coverage Ratios1.671.761.3 K
Very volatile
Operating Cycle215331315
Slightly volatile
Price Book Value Ratio0.981.032.6745
Slightly volatile
Days Of Payables Outstanding10793.8287.3558
Very volatile
Price To Operating Cash Flows Ratio9.9210.4541.4069
Slightly volatile
Company Equity Multiplier1.431.872.0637
Pretty Stable
Long Term Debt To Capitalization0.360.340.3077
Slightly volatile
Total Debt To Capitalization0.380.360.3399
Slightly volatile
Debt Equity Ratio0.630.60.5732
Slightly volatile
Quick Ratio0.640.671.1607
Slightly volatile
Dividend Paid And Capex Coverage Ratio1.931.071.3285
Very volatile
Cash Ratio0.220.230.4949
Slightly volatile
Cash Conversion Cycle138258231
Slightly volatile
Operating Cash Flow Sales Ratio0.230.190.1864
Slightly volatile
Days Of Inventory Outstanding154278230
Slightly volatile
Days Of Sales Outstanding95.7868.6887.9823
Slightly volatile
Cash Flow Coverage Ratios0.160.171.0496
Slightly volatile
Price To Book Ratio0.981.032.6745
Slightly volatile
Fixed Asset Turnover4.152.462.9001
Slightly volatile
Capital Expenditure Coverage Ratio1.631.712.7809
Pretty Stable
Price Cash Flow Ratio9.9210.4541.4069
Slightly volatile
Enterprise Value Multiple18.1211.2127.3585
Slightly volatile
Debt Ratio0.30.290.2559
Slightly volatile
Cash Flow To Debt Ratio0.160.171.0496
Slightly volatile
Price Sales Ratio1.671.753.7317
Slightly volatile
Asset Turnover0.450.320.3575
Slightly volatile
Gross Profit Margin0.780.760.694
Slightly volatile
Price Fair Value0.981.032.6745
Slightly volatile

Takeda Fundamental Market Drivers

Forward Price Earnings38.0228
Cash And Short Term Investments457.8 B

Takeda Upcoming Events

1st of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Takeda Pharmaceutical Financial Statements

Takeda Pharmaceutical investors utilize fundamental indicators, such as revenue or net income, to predict how Takeda Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue126.4 B120.1 B
Total Revenue4.9 T5.1 T
Cost Of Revenue1.6 T1.7 T
Stock Based Compensation To Revenue 0.02  0.01 
Sales General And Administrative To Revenue 0.32  0.46 
Research And Ddevelopement To Revenue 0.17  0.20 
Capex To Revenue 0.10  0.11 
Revenue Per Share2.5 K2.6 K
Ebit Per Revenue 0.06  0.05 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
How To Invest In Takeda
Details
Is Takeda Stock a good investment?
Details
What is Takeda Pharmaceutical's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.
You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.78)
Dividend Share
192
Earnings Share
0.44
Revenue Per Share
1.5 K
Quarterly Revenue Growth
0.03
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY